pretickt

Incyte Corporation (INCY)

Healthcare · end-of-day data as of Oct 16, 2026

Incyte Corporation
INCY · $22.92B
$113.07-3.9%last 60 sessions · close Oct 16, 2026
$86.17$129.9352 weeks
Hold · 29 analystsPT $128.39 +13.6%
  • P/E vs own+0.5%
  • P/E vs sector-48.8%
  • Target upside+13.6%
  • Off 52w high-13.0%
  • Insiders-$14.67M
  • FCF yield+8.4%
  • Earnings in13d
  • Trendsideways
  • Sector▲ +16.0%
  • RSI39
  • MA20×50Death 10d ago
  • Volume0.9x
  • Support-4.0%
  • Resistance+5.8%

The average 12-month analyst price target for INCY is $128.39, 13.6% above the last close of $113.07 on Oct 16, 2026; targets range from $86.22 to $155.41. Rating consensus: Hold.

Snapshot

  • P/E14.4x
  • P/E vs sector-48.8%
  • P/E vs own+0.5%
  • Target upside+13.6%
  • ConsensusHold
  • Market cap$22.92B
  • FCF yield+8.4%
  • Insiders-$14.67M
  • Earnings in13d
  • News1.00

Why it moved

Incyte Corporation (INCY) fell 0.2% on Oct 16, 2026.

The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.

Market (SPY)-1.1%
Healthcare sector+0.4%
INCY specific+0.6%

1 story on the day (30-day average 0.5).

Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.

Price and events

⇔⇕$89.01$102$114$127Oct 25Jan 26Apr 26Jul 26Oct 26EAAAEAEAEE

Last close $113.07 · +29.5% over 1y · E earnings · D dividend · S split · A analyst rating change

Technicals

  • Trendsideways
  • Sector▲ +16.0%
  • MAs20▼ 50▼ 100▼ 200▲
  • Above MAs1 of 4 above
  • MA20×50Death 10d ago
  • RSI39
  • Support-4.0%
  • Resistance+5.8%
  • Off 52w high-13.0%
  • Off ATH-25.9%
  • 52w range$113.07
  • Bollingerlower half
  • MACD-0.38
  • ATR+3.0%
  • Volume0.9x

Analyst price targets

Low$86.22
Average$128.39
Median$128.25
High$155.41
Upside+13.6%

18 firms with a target in the last 12 months · last close $113.07 · as of Oct 16, 2026

⇔⇕$79.01$99.02$119$139$159Oct 25Mar 26Aug 26Jan 27Jun 27-14%+3%-24%-5%+24%-8%+30%+2%
— actual price● bullish target● bearish targethover a dot to see the analysts behind it · wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets

Strong buy 2 · Buy 10 · Hold 15 · Sell 1 · Strong sell 1

Revenue and free cash flow

Q2 FY2026: Revenue +37.7% year over year, free cash flow 29.6% of revenue, operating margin 41.7%.

RevenueFree cash flow
Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026
Q2 FY2026Jun 30, 2026$1.67B2.81$495M93.7%41.7%35.0%
Q1 FY2026Mar 31, 2026$1.27B1.47$359M91.8%25.5%23.8%
Q4 FY2025Dec 31, 2025$1.51B1.46$521M92.0%25.5%19.9%
Q3 FY2025Sep 30, 2025$1.37B2.11$545M92.8%31.6%31.1%
Q2 FY2025Jun 30, 2025$1.22B2.04$25.67M93.5%25.6%33.3%
Q1 FY2025Mar 31, 2025$1.05B0.80$263M93.0%20.6%15.0%
Q4 FY2024Dec 31, 2024$1.18B1.02$364M92.5%25.2%17.1%
Q3 FY2024Sep 30, 2024$1.14B0.54$306M92.4%12.8%9.4%

Peers

20D
1VRTXVertex Pharmaceuticals Incorporated$499.74-1.8%-10.4%+14.0%29.1$127B
2MRNAModerna, Inc.$218.01-7.8%-7.8%-25.0%—$87.04B
3REGNRegeneron Pharmaceuticals, Inc.$790.74-0.7%-7.2%+8.7%19.6$81.41B
4ALNYAlnylam Pharmaceuticals, Inc.$231.83-0.9%-52.8%+61.5%39.2$31.02B
5INCYIncyte Corporation$113.07-0.2%-13.0%+13.6%14.4$22.92B
6STESTERIS plc$222.66-0.7%-16.4%+24.2%27.2$21.71B
7VTRSViatris Inc.$18.66+2.4%0.0%+9.8%—$21.43B
8TECHBio-Techne Corporation$72.57+0.1%-0.1%-7.0%62.6$11.38B

Data as of Oct 16, 2026 close.

Latest news

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.